Archives of Toxicology

, Volume 64, Issue 7, pp 572–579 | Cite as

Disposition, elimination, and metabolism of tri-o-cresyl phosphate following daily oral administration in Fischer 344 male rats

  • Stephen G. Somkuti
  • Mohamed B. Abou-Donia
Article

Abstract

The disposition, elimination, and metabolism of 50 mg/kg (1.36 μCi/animal) of tri-o-cresyl [phenyl-U-14C] phosphate after ten daily oral doses was investigated in adult male Fischer 344 rats. Groups of three treated animals were killed at intervals of 24, 48, 72, and 96 h after the last administrations. Generally, the highest concentrations of radioactive material were excreted via the gastrointestinal tract and the bladder, particularly at the earlier time points. Liver, adipose, epididymis, sciatic nerve tissues; plasma; and red blood cells also contained high concentrations of radioactivity. The lowest concentrations were found in brain, spleen, testes, and heart. Four days after the last dose, the rats had excreted approximately all of the cumulative dose in either urine (63.1%) or feces (36.1%). TOCP and its metabolites in urine, feces, plasma, brain, testes, kidneys, and liver were analyzed by high-performance liquid chromatography and liquid scintillation. Metabolism studies performed 24, 48, 72, and 96 h after administration of the last dose showed that TOCP was the major compound identified in brain, testes, kidneys, plasma, and liver. Liver, additionally, had high levels of di-o-cresyl hydrogen phosphate ando-cresol. TOCP ando-cresol were the predominant compounds in feces; only trace amounts of TOCP were detected in urine. The major metabolites in urine were di-o-cresyl hydrogen phosphate,o-cresol, ando-hydroxy benzoic acid. Testes in rats given ten doses had significantly more TOCP and saligenin cyclic-o-tolyl phosphate than those from rats given a single dose. These results may account for testicular toxicity in rats given daily oral administrations of TOCP but not following a single oral dose.

Key words

Tri-o-cresyl phosphate Pharmacokinetics Oral dosing Rats 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abou-Donia MB (1979) Pharmacokinetics and metabolism of a topically applied dose ofO-4-bromo-2,5-dichlorophenylO-methyl phenylphosphonothioate in hens. Toxicol Appl Pharmacol 51: 311–328PubMedGoogle Scholar
  2. Abou-Donia MB (1980) Metabolism and pharmacokinetics of a single oral dose ofO-4-bromo-2,5-dichlorophenylO-methyl phenylphosphonothioate (Leptophos) in hens. Toxicol Appl Pharmacol 55: 131–145PubMedGoogle Scholar
  3. Abou-Donia MB (1981) Organophosphorous ester-induced delayed neurotoxicity. Annu Rev Pharmacol Toxicol 21: 511–548PubMedGoogle Scholar
  4. Abou-Donia MB (1983) Toxicokinetics and metabolism of delayed neurotoxic organophosphorus esters. Neurotoxicology 4: 511–548Google Scholar
  5. Abou-Donia MB, Lapadula DM (1990) Mechanisms of organophosphorus ester-induced delayed neurotoxicity: type I and type II. Annu Rev Pharmacol Toxicol 30: 405–440PubMedGoogle Scholar
  6. Abou-Donia MB, Nomeir AA (1986) The role of pharmacokinetics and metabolism in species sensitivity to neurotoxic agents. Fundam Appl Toxicol 6: 190–207PubMedGoogle Scholar
  7. Abou-Donia MB, Reichert BL, Ashry MA (1983a) The absorption, distribution, excretion, and metabolism of a single oral dose ofO-ethylO-4-nitrophenyl phenylphosphonothioate in hens. Toxicol Appl Pharmacol 70: 18–28PubMedGoogle Scholar
  8. Abou-Donia MB, Sivarajah K, Abou-Donia SA (1983b) Disposition, elimination and metabolism ofO-ethyO-4-nitrophenyl phenylphosphonothioate after subchronic dermal application in male cats. Toxicology 26: 93–111PubMedGoogle Scholar
  9. Abou-Donia MB, Patton SE, Lapadula DM (1984) Possible role of endogeneous protein phosphorylation in organophosphorus compound-induced neurotoxicity. In: Narahashi T (ed) Cellular and molecular neurotoxicology. Raven Press, New York, pp 265–283Google Scholar
  10. Abou-Donia MB, Suwita E, Nomeir AA (1990) Absorption, distribution, and elimination of a single oral dose of [14C]tri-o-cresyl phosphate in hens. Toxicology 61: 12–25Google Scholar
  11. Ames BN, McCann J, Yamasaki E (1975) Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutat Res 31: 347–364PubMedGoogle Scholar
  12. Bischoff KB, Dedrick RL, Zaharko DS, Longstreth JA (1971) Methotrexate pharmacokinetics. J Pharm Sci 60: 1128–1133PubMedGoogle Scholar
  13. Bleiberg MJ, Johnson H (1965) Effect of certain metabolically active drugs and oximes on tri-o-cresyl phosphate toxicity. Toxicol Appl Pharmacol 7: 227–235Google Scholar
  14. Buttar HS, Tyrrell DL, Taylor JD (1968) Effect of tri-o-cresyl phosphate, tri-o-cresyl thiophosphate and 2-(o-cresyl)-4H: 1∶3∶2 benzodioxaphosphoran-2-one on pentobarbital induced sleeping time in mice. Arch Int Pharmacodyn 172: 373–379PubMedGoogle Scholar
  15. Casida JE, Eto M, Baron RL (1961) Biological activity of a tri-o-cresyl phosphate metabolite. Nature 191: 1396–1397PubMedGoogle Scholar
  16. Chapin R, Phelps J (1989) Tri-o-cresyl phosphate (TOCP) toxicity to sertoli cells in vitro requires Leydig cells. Toxicologist 9: 66Google Scholar
  17. Eto M, Casida JE, Eto T (1962) Hydroxylation and cyclization reactions involved in the metabolism of tri-o-cresyl phosphate. Biochem Pharmacol 11: 337–352PubMedGoogle Scholar
  18. Eto M, Oshima Y, Casida JE (1967) Plasma albumin as a catalyst in cyclization of diarylO-(hydroxyl)tolyl phosphates. Biochem Pharmacol 16: 295–308PubMedGoogle Scholar
  19. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, Inc., New York, pp 1–5Google Scholar
  20. Hodgson E, Dauterman WC (1980) Metabolism of toxicants: phase 1 reactions. In: Hodgson E, Guthrie FE (eds) Introduction to biochemical toxicology. Elsevier, New York, pp 67–105Google Scholar
  21. Lapadula DM, Patton SE, Campbell GA, Abou-Donia MB (1985) Characterization of delayed neurotoxicity in the mouse following chronic oral administration of TOCP. Toxicol Appl Pharmacol 79: 83–90PubMedGoogle Scholar
  22. Lasker JM, Graham DG, Abou-Donia MB (1982) Differential metabolism ofO-4-nitrophenyl phenylphosphonothioate by rat and chicken hepatic microsomes. Biochem Pharmacol 31: 1961–1967PubMedGoogle Scholar
  23. Milne MD, Schribner BN, Craford MA (1958) Non-ionic diffusion and excretion of weak acids and bases. Am J Med 24: 709PubMedGoogle Scholar
  24. Mukhtar H, Lee IP, Tooreman CL, Bend JR (1978) Epoxide metabolizing activities in rat testes: postnatal development and relative activity in interstitial and spermatogenic cell compartment. Chem Biol Interact 22: 153–165PubMedGoogle Scholar
  25. Nakatsugawa T, Morelli MA (1976) Microsomal oxidation and insecticide metabolism. In: Wilkinson CF (ed) Insecticides biochemistry and physiology. Plenum Press, New York, pp 61–114Google Scholar
  26. Nomeir AA, Abou-Donia MB (1983) High performance liquid chromatographic analysis on radial compression column of the neurotoxic tri-o-cresyl phosphate and metabolites. Anal Biochem 135: 296–303PubMedGoogle Scholar
  27. Nomeir AA, Abou-Donia MB (1984) Disposition of [14C]tri-o-cresyl phosphate and its metabolites in various tissues of the male cat following a single dermal application. Drug Metab Dispos 12: 705–711PubMedGoogle Scholar
  28. Nomeir AA, Abou-Donia MB (1986a) Studies on the metabolism of the neurotoxic tri-o-cresyl phosphate. Synthesis and identification by infrared, proton nuclear magnetic resonance and mass spectrometry of five of its metabolites. Toxicology 38: 1–13PubMedGoogle Scholar
  29. Nomeir AA, Abou-Donia MB (1986b) Studies on the metabolism of the neurtoxic tri-o-cresyl phosphate. Distribution, excretion, and metabolism in male cats after a single, dermal application. Toxicology 38: 15–33PubMedGoogle Scholar
  30. Nomeir AA, Dauterman WC (1979) In vitro metabolism of EPN and EPNO by mouse liver. Pestic Biochem Physiol 10: 190–196Google Scholar
  31. Nomeir AA, Makkawy HA, Bower JA, Abou-Donia MB (1984) Distribution and metabolism of [14C]-tri-o-cresyl phosphate (TOCP) in the male rat following oral administration. Toxicologist 4: 90Google Scholar
  32. Patton SE, Lapadula DM, Abou-Donia MB (1985a) Partial characterization of endogenous phosphorylation condition for hen brain cytosolic and membrane proteins. Brain Res 328: 1–14PubMedGoogle Scholar
  33. Patton SE, Lapadula DM, Abou-Donia MB (1985b) Comparison of endogenous phosphorylation of hen and rat spinal cord proteins and partial characterization of optimal phosphorylation conditions for hen spinal cord. Neurochem Int 7: 111–123Google Scholar
  34. Payne AH, Quinn PG, Sheela-Rani CS (1985) Regulation of microsomal cytochrome P-450 enzymes and testosterone production in Leydig cells. In: Greep RO (ed) Recent progress in hormone research, vol 41. Academic Press, New York, pp 153–197Google Scholar
  35. Sharma RP, Watanabe PG (1974) Time related disposition of tri-o-tolyl phosphate (TOTP) and metabolites in chicken. Pharmacol Res Commun 6: 415–484Google Scholar
  36. Smith MI, Elvove E, Frazier WH (1930) The pharmacological action of certain phenol esters, with special reference to the etiology of socalled ginger paralysis. Public Health Rep 45: 2509–2524Google Scholar
  37. Somkuti SG, Lapadula DM, Chapin RE, Lamb JC IV, Abou-Donia MB (1987a) Testicular toxicity following oral administration of tri-o-cresyl phosphate (TOCP) in roosters. Toxicol Lett 37: 279–290PubMedGoogle Scholar
  38. Somkuti SG, Lapadula DM, Chapin RE, Lamb JC IV, Abou-Donia MB (1987b) Reproductive tract lesions resulting from subchronic administration (63 days) of tri-o-cresyl phosphate in male rats. Toxicol Appl Pharmacol 89: 49–63PubMedGoogle Scholar
  39. Somkuti SG, Lapadula DM, Chapin RE, Lamb JCIV, Abou-Donia MB (1987c) Time course of the tri-o-cresyl phosphate-induced testicular lesion in F-344 rats: enzymatic, hormonal, and sperm parameter studies. Toxicol Appl Pharmacol 89: 64–72PubMedGoogle Scholar
  40. Somkuti SG, Chapin RE, Lapadula DM, Othman MA, Abou-Donia MB (1988a) The metabolism of tri-o-cresyl phosphate (TOCP) by rat testis. Toxicologist 8: 118Google Scholar
  41. Somkuti SG, Tilson HA, Brown HR, Campbell GA, Lapadula DM, Abou-Donia MB (1988b) Lack of delayed neurotoxic effect after tri-o-cresyl phosphate treatment in male Fischer 344 rats: biochemical, neurobehavioral, and neuropathological studies. Fundam Appl Toxicol 10: 199–205PubMedGoogle Scholar
  42. Suwita E, Abou-Donia MB (1990) Pharmacokinetics and metabolism of a single subneurotoxic oral dose of tri-o-cresyl phosphate in hens. Arch Toxicol (in press)Google Scholar
  43. Taylor JD, Buttar HS (1967) Evidence for the presence of 2-(o-cresyl)-4H-1,3,2-benzodioxaphosphoran-2-one in cat intestine following tri-o-cresyl phosphate administration. Toxicol Appl Pharmacol 11: 529–537PubMedGoogle Scholar
  44. Veronesi B (1984) A rodent model of organophosphate-induced delayed neuropathy: distribution of central (spinal cord) and peripheral nerve damage. Neuropathol Appl Neurobiol 10: 357–368PubMedGoogle Scholar
  45. Whitacre DM, Badie M, Schwemmer BA, Diaz L (1976) Metabolism of14C-leptophos and14C-4-bromo-2.5-dichlorophenol in rats: a multiple dosing study. Bull Environ Contam Toxicol 16: 689–696PubMedGoogle Scholar
  46. Windholz M, Budavari S, Bluwetti RF, Otterbein EE (eds) (1983) The Merck Index: an encyclopedia of chemicals, drugs and biologicals. Merck and Co., Inc., Rahwey, NJGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • Stephen G. Somkuti
    • 1
  • Mohamed B. Abou-Donia
    • 1
  1. 1.Department of PharmacologyDuke University Medical CenterDurhamUSA

Personalised recommendations